Open AccessEculizumab application during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: A case report with review of the literature
Author(s) -
LauritschHernandez Lisa Sophie,
Kraehenmann Franziska,
Balabanov Stefan,
Kimmich Nina
Publication year - 2018
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1634
Subject(s) - paroxysmal nocturnal hemoglobinuria , eculizumab , medicine , pregnancy , hemoglobinuria , intensive care medicine , pediatrics , preeclampsia , anemia , complement system , immunology , antibody , biology , genetics
Key Clinical Message Eculizumab is highly effective in inhibiting complement activation and has successfully shown to prevent complications and to improve quality of life in patients with paroxysmal nocturnal hemoglobinuria ( PNH ). Its application during pregnancy showed favorable fetal and maternal outcome in the presented case and has proven to be effective without raising safety concerns.